{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:42:26Z","timestamp":1786372946994,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.2215\/cjn.07161009","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T20:35:32Z","timestamp":1269549332000},"page":"856-866","source":"Crossref","is-referenced-by-count":18,"title":["Modeling the 4D Study"],"prefix":"10.2215","volume":"5","author":[{"given":"Kevin E.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20230601","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"key":"R4-19-20230601","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2215\/CJN.00080106","article-title":"Cohort studies: Marching forward","volume":"1","author":"Thadhani","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R5-19-20230601","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMp058267","article-title":"Observational studies of drugs and mortality","volume":"353","author":"Ray","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-19-20230601","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1046\/j.1523-1755.2000.07413.x","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study","volume":"57","author":"Young","year":"2000","journal-title":"Kidney Int"},{"key":"R8-19-20230601","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.ajkd.2008.12.001","article-title":"Randomized and observational studies in nephrology: How strong is the evidence?","volume":"53","author":"Greene","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R9-19-20230601","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-19-20230601","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1046\/j.1523-1755.1999.07158.x","article-title":"Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators","volume":"71","author":"Wanner","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"R11-19-20230601","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1681\/ASN.2008080824","article-title":"Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R12-19-20230601","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ki.2009.199","article-title":"Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge","volume":"76","author":"Chan","year":"2009","journal-title":"Kidney Int"},{"key":"R13-19-20230601","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","article-title":"Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R14-19-20230601","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/j.ajkd.2008.07.031","article-title":"Associates of mortality and hospitalization in hemodialysis: Potentially actionable laboratory variables and vascular access","volume":"53","author":"Lacson","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R15-19-20230601","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1046\/j.1523-1755.2001.00029.x","article-title":"Association between prevalent care process measures and facility-specific mortality rates","volume":"60","author":"Lowrie","year":"2001","journal-title":"Kidney Int"},{"key":"R16-19-20230601","first-page":"199","article-title":"Public Health Information Network: Improving early detection by using a standards-based approach to connecting public health and clinical medicine","volume":"53","author":"Broome","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R20-19-20230601","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529684","article-title":"Matching to remove bias in observational studies","volume":"29","author":"Rubin","year":"1973","journal-title":"Biometrics"},{"key":"R21-19-20230601","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J Am Stat Assoc"},{"key":"R22-19-20230601","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1020371312283","article-title":"Estimation of causal effects using propensity score weighting: An application to data on right heart catheterization","volume":"2","author":"Hirano","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"R23-19-20230601","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effect","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"R24-19-20230601","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"R25-19-20230601","first-page":"349","article-title":"Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease","volume":"47","author":"Hunninghake","year":"1998","journal-title":"J Fam Pract"},{"key":"R26-19-20230601","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0149-2918(98)80063-5","article-title":"A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia","volume":"20","author":"Sasaki","year":"1998","journal-title":"Clin Ther"},{"key":"R27-19-20230601","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/biomet\/87.3.706","article-title":"The role of propensity score in estimating dose-response in observational studies for causal effect","volume":"3","author":"Imbens","year":"2000","journal-title":"Biometrika"},{"key":"R29-19-20230601","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1046\/j.1523-1755.2000.00945.x","article-title":"Vintage, nutritional status, and survival in hemodialysis patients","volume":"57","author":"Chertow","year":"2000","journal-title":"Kidney Int"},{"key":"R30-19-20230601","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM197607082950204","article-title":"Randomized clinical trials: Perspectives on some recent ideas","volume":"295","author":"Byar","year":"1976","journal-title":"N Engl J Med"},{"key":"R31-19-20230601","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJM200006223422511","article-title":"Randomized trials or observational tribulations?","volume":"342","author":"Pocock","year":"2000","journal-title":"N Engl J Med"},{"key":"R32-19-20230601","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R33-19-20230601","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R34-19-20230601","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"R37-19-20230601","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"},{"key":"R38-19-20230601","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"R39-19-20230601","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ajkd.2003.07.016","article-title":"Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences","volume":"42","author":"Kalantar-Zadeh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R40-19-20230601","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"R41-19-20230601","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.amjcard.2006.09.125","article-title":"The inflammation hypothesis and its potential relevance to statin therapy","volume":"99","author":"Forrester","year":"2007","journal-title":"Am J Cardiol"},{"key":"R42-19-20230601","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R43-19-20230601","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: A critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"R44-19-20230601","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R45-19-20230601","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"R46-19-20230601","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"R48-19-20230601","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"R49-19-20230601","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7326\/0003-4819-151-3-200908040-00126","article-title":"Rethinking randomized clinical trials for comparative effectiveness research: The need for transformational change","volume":"151","author":"Luce","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201005000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:35Z","timestamp":1786369175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201005000-00019"}},"subtitle":["Statins and Cardiovascular Outcomes in Long-Term Hemodialysis Patients with Diabetes"],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.07161009","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}